17 powodów, dla których warto stosować cilostazol Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2015
Słowa kluczowe:
choroba tętnic kończyn dolnych, chromanie przestankowe, cilostazol
##plugins.themes.bootstrap3.article.main##
Abstrakt
Choroba tętnic kończyn dolnych jest poważnym problemem klinicznym wpływającym na jakość życia oraz rokowanie pacjentów. Najczęściej objawia się chromaniem przestankowym, co może wpływać na sprawność ruchową. Podstawą leczenia choroby tętnic kończyn dolnych jest zaprzestanie palenia, trening marszowy oraz farmakoterapia lekiem przeciwpłytkowym i statyną. W przypadku utrzymywania się chromania przestankowego pomimo treningu marszowego oraz zaprzestania palenia można zastosować leki wydłużające dystans chromania przestankowego.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Balsam , P., & Grabowski , M. (2015). 17 powodów, dla których warto stosować cilostazol . Medycyna Faktów , 8(1(26), 44-49. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2323
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. European Stroke O., Tendera M., Aboyans V. et al.: ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal 2011; 32(22): 2851-2906.
2. Schmieder F.A., Comerota A.J.: Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. The American Journal of Cardiology 2001; 87(12A): 3D-13D.
3. Alonso-Coello P., Bellmunt S., McGorrian C. et al.: Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl.): e669S-90S.
4. Gogarten W., Vandermeulen E., van Aken H. et al.: Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. European Journal of Anaesthesiology 2010; 27(12): 999-1015.
5. Takahashi S., Oida K., Fujiwara R. et al.: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. Journal of Cardiovascular Pharmacology 1992; 20(6): 900-906.
6. Norgren L., Hiatt W.R., Dormandy J.A. et al.: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular surgery: the Official Journal of the European Society for Vascular Surgery 2007; 33 Suppl. 1: S1-75.
7. Bedenis R., Stewart M., Cleanthis M. et al.: Cilostazol for intermittent claudication. The Cochrane database of systematic reviews 2014; 10:CD003748.
8. Shinohara Y., Katayama Y., Uchiyama S. et al.: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurology 2010; 9(10): 959-968.
9. Charakterystyka produktu leczniczego Decilosal 100 mg 17.01.2014.
10. Hiatt W.R., Money S.R., Brass E.P.: Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). Journal of Vascular Surgery 2008; 47(2): 330-336.
11. Soga Y., Yokoi H., Kawasaki T. et al.: Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. Journal of the American College of Cardiology 2009; 53(1): 48-53.
12. Iida O., Yokoi H., Soga Y. et al.: Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013; 127(23): 2307-2315.
13. Iida O., Nanto S., Uematsu M. et al.: Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. Journal of Vascular Surgery 2008; 48(1): 144-149.
14. Shin E.S., Lee J.H., Yoo S.Y. et al.: A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina. Heart 2014; 100(19): 1531-1536.
15. Elam M.B., Heckman J., Crouse J.R. et al.: Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology 1998; 18(12): 1942-1947.
16. Dawson D.L., Cutler B.S., Hiatt W.R. et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. The American Journal of Medicine 2000; 109(7): 523-530.
17. Chong E., Ensom M.H.: Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23(4): 460-471.
18. Lee T.M., Su S.F., Hwang J.J. et al.: Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis 2001; 158(2): 471-476.
19. Agrawal N.K., Maiti R., Dash D., Pandey B.L.: Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacological Research: the Official Journal of the Italian Pharmacological Society 2007; 56(2): 118-123.
2. Schmieder F.A., Comerota A.J.: Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. The American Journal of Cardiology 2001; 87(12A): 3D-13D.
3. Alonso-Coello P., Bellmunt S., McGorrian C. et al.: Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl.): e669S-90S.
4. Gogarten W., Vandermeulen E., van Aken H. et al.: Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. European Journal of Anaesthesiology 2010; 27(12): 999-1015.
5. Takahashi S., Oida K., Fujiwara R. et al.: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. Journal of Cardiovascular Pharmacology 1992; 20(6): 900-906.
6. Norgren L., Hiatt W.R., Dormandy J.A. et al.: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular surgery: the Official Journal of the European Society for Vascular Surgery 2007; 33 Suppl. 1: S1-75.
7. Bedenis R., Stewart M., Cleanthis M. et al.: Cilostazol for intermittent claudication. The Cochrane database of systematic reviews 2014; 10:CD003748.
8. Shinohara Y., Katayama Y., Uchiyama S. et al.: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurology 2010; 9(10): 959-968.
9. Charakterystyka produktu leczniczego Decilosal 100 mg 17.01.2014.
10. Hiatt W.R., Money S.R., Brass E.P.: Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). Journal of Vascular Surgery 2008; 47(2): 330-336.
11. Soga Y., Yokoi H., Kawasaki T. et al.: Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. Journal of the American College of Cardiology 2009; 53(1): 48-53.
12. Iida O., Yokoi H., Soga Y. et al.: Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013; 127(23): 2307-2315.
13. Iida O., Nanto S., Uematsu M. et al.: Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. Journal of Vascular Surgery 2008; 48(1): 144-149.
14. Shin E.S., Lee J.H., Yoo S.Y. et al.: A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina. Heart 2014; 100(19): 1531-1536.
15. Elam M.B., Heckman J., Crouse J.R. et al.: Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology 1998; 18(12): 1942-1947.
16. Dawson D.L., Cutler B.S., Hiatt W.R. et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. The American Journal of Medicine 2000; 109(7): 523-530.
17. Chong E., Ensom M.H.: Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23(4): 460-471.
18. Lee T.M., Su S.F., Hwang J.J. et al.: Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis 2001; 158(2): 471-476.
19. Agrawal N.K., Maiti R., Dash D., Pandey B.L.: Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacological Research: the Official Journal of the Italian Pharmacological Society 2007; 56(2): 118-123.